// App-Quantinova.ai

POS0926 (2021) : NORMALIZATION OF HIGH SENSITIVITY CRP VERSUS CLINICAL RESPONSE TO IXEKIZUMAB AT WEEK 16 IN PATIENTS WITH RADIOGRAPHIC & NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE COAST STUDIES

Researchers

Presenter

  • H. Marzo-Ortega

Principal Investigators

  • X. Juanola

  • T. Okano

  • Y. Schymura

  • A. Bradley

  • J. Gerwien

  • S. Liu Leage

  • D. Aletaha

  • M. stergaard

Medical Centers

  • Leeds Teaching Hospitals NHS Trust & LIRMM, University of Leeds, NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom

  • University Hospital Bellvitge, Rheumatology Service, Barcelona, Spain

  • Osaka University Graduate School of Medicine, Suita, Japan

  • Eli Lilly and Company, Indianapolis, United States of America

  • Eli Lilly and Company, Medical Rheumatology, Indianapolis, United States of America

  • Eli Lilly and Company, Indianapolis, United States of America

  • Medical University of Vienna, Division of Cardiology, Vienna, Austria

  • University of Copenhagen, Dept. of Forensic Medicine, Copenhagen, Denmark

Locations

  • United Kingdom

  • Spain

  • Japan

  • United States

  • Austria

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Non-radiographic axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

  • Axial spondyloarthritis

Biomarkers

  • C reactive protein

  • High sensitivity C-reactive protein

Drug/Treatment

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Multinational

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02696798

  • NCT02757352

Sponsors

  • Janssen Pharmaceutical

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved